METHOD OF PROFILING GENES AS RISK FACTORS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER Serial No. 09/825,922 Sheet 1 of 11

	77			5								
Gene	= z	Mean	SD	2 2	Mean	S	3 Z	Mean	S	F-ratio	α.	Gene score
Dopamine genes												
Lit Optimized	33	20.10	10.2	164	17.58	1	33	18.30	10.9	0.848	0.43	201
Optimized	री	15.93	10.3	120	19.50	10.2	7 5	17.51	4.	1.560	0.21	020 021
DADS SINF MISCI Lit Optimized	152	17.68	1	157	18.34	11.0	27	19.16	9.6	0.495	0.63	202
DAD4 140 bp repeat Lit Optimized	20	19.00	10.9	162	17.98	10.5	78	17.86	11.6	0.223	0.80	005 200
UKD3 2 dinucleotide repeat Lit Optimized	74	18.63	11.4	£	19.15	11.3	151	17.38	10.6	0.881	0.41	220 120
DAT1 3 repeat Lit Optimized	21	15.33	12.4	142	17.41	10.9	173	19.07	10.8	1.619	0.20	012 012
Serotonin genes HTT ⁴ (SLC6A4) promoter ins/del												
Optimized	85	16.20	10.9	159	19.11	10.9	91	18.28	11.3	1.953	0.14	027
Ind Ind Optimized	82	19.00	10.61	171	17.31	4.	11	19.89	10.1	1.683	610	022 102

that the limb man was the first with the limb

3. 1A-1

David E. Comings METHOD OF PROFILING GENES AS RISK FACTORS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER Serial No. 09/825,922 Sheet 2 of 11

	1			5		5				E rofio	ء	Gene conte
Gene	= z	Mean	S	<u> </u>	Mean		Mean	an SD		ם מוס	2 .	
HTR1B (HTR1DB) SNP G861C					i i		ē					SC
Lit Optimized	202	18.49	10.9	107	17.30	11.1	27	19.00	11.5	0.496	0.61	102
HTR/1DA SNP T1350C												02-
Optimized	766	18.16	11.3	70	19.34	9.7	اح	1	ı	0.641	0.43	02-
n i kza sinf i 1020 msp.i Lit Optimized	28	17.88	11.2	172	18.59	11.0	901	17.61	11.0	0.279	0.76	012 020
7DO2 SNP G-> A Int 6Bs/l							ı					02-
Optimized Care Care Care Care Care Care Care Care	315	17.98	11.0	11	20.65	10.4	ا ت	ı	1	0.951	0.33	-20
Lit		9	9	9	7.70	0 0	g	20	<u> </u>	0.705	0.405	200
Optimized Norepinephrine genes	8	90. 81.		<u>8</u>	C1:11	0.0	S	07:61	<u>.</u>	3	9	1
DBH SNP Tag I												220
Optimized	67	18.81	10.1	168	18.78	11.1	101	16.69	11.3	1.285	0.28	220
ADRA2A SNP promoter region Mspl												012
Optimized	186	17.42	11.1	128	18.8	10.5	72	21.95	11.7	1.96	0.14	012
ADRA2B del/ins Ind												102
Dotimized	155	18.14	11.5	158	18.46	10.6	23	19.73	9.6	0.215	0.81	005
ADRA2C 6 dinucleotide repeat												202
ind Optimized	131	18.77	10.5	113	15.79	11.0	35	20.17	11.2	4.45	0.012	102
				Ī	7	< <						

	David E. Comings	
METHOD OF PROFILE	NG GENES AS RISK FACTO	RS FOR ATTENTION
DEFIC	CIT HYPERACTIVITY DISOR	RDER
	Serial No. 09/825,922	
	Sheet 3 of 11	

Gene	=			12			22			F-ratio	۵	Gene score
	Z	Mean	S	Z	Mean SD	S	Z	Mean SD	S		L	
NET (SLC6A2) SNP A1970G Mnil												150
Optimized C-148A	155	17.82	11.2	144	19.04	10.6	88	16.6	11.3	0.914	0.405	120
Ind Ind Optimized	110	16.89	1.1	156	19.59	10.9	99	17.58	10.9	2.05	0.129	012 021
COM1 SNP val 158 met, G1947A, Malll Ind Optimized	75	19.42	10.8	175	18.52	11.0	8	16.52	10.8	1.55	0.212	210 210

Lif, references for literature-based gene scoring; Ind, gene scoring based on our studies of an independent set of subjects; SNP, single nucleotide polymorphism. 1DRD4: 11=any<4; 12=4/4; 22=any>4. 2DRD5: 11= 148/148; 12=44; 22=any>4. 2DRD5: 11= 148/148; 12=het; 22=non 148/non 148. 3DAT7: 11=non 10/non 10; 12= 10/non 10; 22=10/10. 4HTT: 11=SS; 12=SL; 22=LL. 5HTR1DA, TDO2 since there were only 2 22s, they were combined with the 12s. 6ADRA2C:11= <183/<183; 12=het; 22=183/183

FIG. 1A-3

David E. Comings METHOD OF PROFILING GENES AS RISK FACTORS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER Serial No. 09/825,922 Sheet 4 of 11

Gene	9	11 % Mean S	S.D.	% Me	1 <u>2</u> ean S.E	õ.	<u>«</u> М	<u>22</u> ean S.D.		F-ratio	p	Gene Score
Other N	leurotra	ansmitter :	Genes									
HTR6 S	SNP (S	hinkai et a	ıl. 1998)									
ADHD	2.8	12.33	9.7	27.1	18.26	10.3	70.0	18.66	11.2	1.44	.23	012
ODD		3.0	2.3		3.91	3.1		3.64	3.2	.44	.64	021
CD		2.11	1.5		3.65	2.6		3.17	2.6	2.05	.13	022
GABRB	3 dinu	cleotide re	peat (M	utiran	gura et a	al. 199	12)a					
ADHD	38.0	18.99	10.8	47.9	17.48	11.1	14.1	19.69	10.9	1.05	.35	102
ODD		3.57	3.1		3.55	3.2		4.47	3.1	1.67	.18	002
CD		3.01	2.2		2.97	2.4		2.91	2.4	.089	.91	200
GABBR	1 dinu	cleotide re	peat (ur	publis	shed)b							
ADHD	9.5	17.5	11.7	27.0	19.1	11.7	63.5	18.2	10.5	.28	.752	020
ODD		3.54	3.7		3.66	3.1		3.72	3.1	.047	.953	012
CD		3.45	2.6		2.72	2.2		3.02	2.4	1.24	.291	201
CNR1 (Cannal	oinoid 1 re	eceptor)	(Daws	on 199	5)C						
ADHD	10.6	19.35	10.9	44.7	18.25	11.0	44.7	18.13	10.9	.174	.83	200
ODD		4.67	3.1		3.54	3.1		3.56	3.2	1.89	.15	200
CD		3.09	2.2		2.90	2.3		3.03	2.4	.146	.86	202
CHRNA	4 (Cho	linergic, n	icotinic,	alpha	4) (Wei	land, S	Steinleir	1996) ^d				
ADHD	8.0	22.19	9.2 3	6.2	18.90	10.8	55.8	17.19	11.2	2.35	.096	210
ODD		5.07	3.0		3.59	3.0		3.55	3.2	2.74	.065	200
CD		3.11	2.1		2.93	2.3		2.99	2.4	.071	.930	200

FIG. 1B-1

David E. Comings METHOD OF PROFILING GENES AS RISK FACTORS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER Serial No. 09/825,922 Sheet 5 of 11

11110101	/ D		007) 11 11	ON ID							
NMDAR1	(Rupp	et al. 1	997) Hpa II :	SNP							
ADHD	44.2	17.31	10.7 45.7	19.31	11.0	10.1	18.56	11.3	1.19	.303	021
ODD		3.79*	3.1	3.79*	3.1		4.84	3.1	2.93	.054	002
CD		2.83	2.3	3.07	2.3		3.28	2.7	.649	.523	012
ADORA2	4 (ader	nosine 2	A receptor)	(Deckei	t et al.	1996) (C 108 T R	sa I.			
ADHD	33.2	19.95	10.4 44.7	17.57	11.0	22.0	18.97	10.8	1.48	.229	201
ODD		4.04	3.3	3.41	3.1		4.02	3.1	1.52	.219	202
CD		3.39	2.5	2.82	2.1		2.83	2.4	2.04	.131	200
GRIN2B (glutam	ate iono	otropic, NMD	OA 2B re	ceptor) T/G (S	SNP datal	base V	VIAF-1	189).	
ADHD	20.9	17.94	10.6 52.3	19.35	10.6	26.8	18.10	11.1	.582	.559	021
ODD		3.03*	3.0	4.15	3.1		3.50	3.1	3.22	.041	021
CD		2.36*	2.0	3.28	2.4		2.98	2.3	3.59	.029	021
MOS2 (nit	rio ovio	la avath	ase 3) (War	na of al	1006)						
MOSS (IIII	IIC OXIC	ie Syriui	ase s) (vvai	ıy et ai.	1990)						
ADHD	67.5	18.50	10.9 25.0	18.60	10.6	7.5	17.12	11.6	.186	.830	220
ODD		3.72	3.1	3.87	3.3		3.29	3.1	.311	.733	120
CD		3.00	2.3	3.12	2.2		2.33	1.9	1.08	.339	120
Opoids											
PENK (pro	enkep	halin) (\	Weber, May	1990; C	oming	s et al.	1999a) ^e				
ADHD	32.1	18.71	10.4 47.4	18.02	11.3	20.6	18.25	11.0	.053	.948	201
ODD		3.75	3.2	3.75	3.2		3.48	3.1	.255	.775	220
CD		3.03	2.4	3.00	2.4		2.92	2.2	.041	.959	220

FIG. 1B-2

MME (enke	ephalin	ase) (se	e Metl	nods) ^f .								
ADHD	33.9	19.44	11.0	50.9	17.34	10.9	15.2	19.53	10.9	1.26	.284	202
ODD		3.98	3.2	25	3.44	3.1		3.95	3.0	1.00	.369	202
CD		3.10	2.4	•	2.81	2.3		3.32	2.4	1.08	.340	202
ANPEP (ar	ninope	ptidase l	N) (Wa	att. Will	ard 199	0) and	see Me	thods. A	\ 257 (3		
ADHD	27.7	19,25			18.37	•	20.8	17.60	11.4	.398	.672	210
ODD		3.65	3.1		3.95			3.30	3.2		.389	120
CD		3.12	2.4		3.05			2.42	2.0	1.96	.142	210
NAT1 (N-ad	cetyl tra	ansferas	e) T 1	088 A (Dietz et	al. 199	97; Com	nings et	al. 200	0)		
ADHD	5.7	21.50	9.5	34.7	19.00	11.2	59.6	17.86	10.8	1.11	.329	210
ODD		4.94	3.7		3.51	3.2		3.68	3.1	1.58	.207	200
CD		4.11	2.8		3.00	2.3		2.88	2.2	2.26	.106	210
Hormones	and ne	uropepti	des									
ESR1 (estr	ogen ´	1 recept	or) dir	ucleoti	de repe	at (del	Senno	et al. 19	92; Co	mings e	et al. 19	999).
ADHD	27.3	19.08	12.0	41.2	17.52	10.6	31.5	18.90	10.3	.673	.511	201
ODD		3.82	3.4		3.56	3.0		3.86	3.0	.293	.746	202
CD		3.26	2.6		2.53*	2.0		3.33	2.5	4.09	.017	202
CYP19 (ard	matas	e cvtoch	rome	P - 450)) dinucl	eotide	repeat ((Polvme	ropoul	os et al	. 1991b)g
ADHD		16.88			•		-		•	2.11	.122	
ODD	. 411	3.50	3.1		3.33			4.11		2.16	.116	102
CD		3.07			2.52*			3.37		4.61	.011	102
J D		0.01	4 , 7		2.02	<i></i> . <i></i>		0.01	∠. , r	1.01	.011	102

FIG. 1B-3

SHBP (se	ex horn	none bir	nding p	orotein)	(Xu,Li 1	998)						
ADHD	59.8	18.39	11.2	35.2	18.38	10.4	5.0	17.44	11.4	.057	.944	220
ODD		3.61	3.1		3.76	3.1		3.50	3.1	.108	.897	120
CD		2.85	2.3		3.11	2.3		3.06	1.8	.465	.628	021
CRH (cor	ticoste	rioid rele	easing	hormo	ne) (<i>Xn</i>	n I, G	enome	Databas	e)			
ADHD	89.8	18.25	11.1	8.6	18.78	8.8	1.5	25.00	7.9	1.189	.285	012
ODD		3.66	3.2		3.71	2.8		5.60	3.2	.972	.380	012
CD		2.96	2.4		3.10	2.1		3.80	3.3	.370	.691	012
OXTR (ox	ytocin	recepto	r) (Lia	o et al.	1996) s	ilent C	:->T in	exon 3				
ADHD	47.1	18.48	10.5	44.3	1 8.0	11.5	8.7	20.11	10.7	.431	.650	102
ODD		3.59	3.1		3.65	3.2		4.39	2.8	.776	.461	012
CD		2.77	2.3		3.14	2.3		3.14	2.4	1.06	.347	022
CCK C-45	i T(Ishi	guro et	al. 199	99)								
ADHD	77.0	18.57	10.8	20.4	17.66	11.0	2.2	19.71	14.3	.227	.797	102
ODD		3.83	3.2		3.30	2.9		3.00	3.0	.909	.404	210
CD		3.04	2.4		2.71	2.2		3.14	2.3	.555	.574	102
INS (Hoba	an,Kels	ey 1991	l; Gad	e-Anda	avolu et	al. 199	9)					
ADHD	58.6	18.04	10.8	36.7	18.47	11.1	4.7	19.46	11.2	.147	.863	012
ODD		3.68	3.2		3.70	3.1		3.66	3.6	.0014	.998	120
CD		2.95	2.3		2.98	2.4		3.47	1.6	.334	.716	002
CD8 (Poly	merop	oulos et	al. 19	91a)h								
ADHD	23.2	17.5	11.3	44.3	18.54	10.9	32.5	18.42	10.9	.122	.885	021
ODD		3.31	3.2		4.09	3.2		3.44	3.0	1.95	.143	021
CD		2.53	2.1		3.27	2.5		2.92	2.1	2.44	.088	021

FIG. 1B-4

INFG (Wu, Comings 1998)

ADHD	21.8 18.22	10.9 58.3	18.17	10.9	27.9	18.82	10.8	.109	.896	102
ODD	3.78	2.97	3.69	3.2		3.60	3.2	.068	.934	210
CD	3.11	2.4	3.01	2.4		2.82	2.0	.333	.717	210

PSI (Scott et al. 1996)

ADHD	36.0 17.78	11.1	48.0	18.56	10.6	15.2	18.19	11.6	.215	.806	021
ODD	3.44	3.3		3.92	3.1		3.57	3.1	.828	.438	021
CD	2.59	2.1		3.18	2.4		3.30	2.5	2.68	.069	012

^{*}Significantly lower than highest value by tukey test at α = .05.

- a 11 = <188/<188, 12 = het. 22 = =188/=188
- b 11 = =10/=10, 12 = het. 22=>10/>10
- c 11 = <5/<5 12=het. 22 = =5/=5
- d 11 = =131/=131 12 = het. 22 = >131/>131
- e 11 = =178/=178 12 = het. 22 = >178/>178
- f 11 = a-c/a-c 12 = het. 22 = d-g/d-g
- 9 11 = <4/<4 12 = het. 22 = =4/=4

FIG. 1B-5

Trait	r	r ²	adjusted r ²	F	р	# genes
ADHD	.466	.217	.16	3.82	<.0001	22
ODD	.443	.196	.14	3.58	<.0001	20
CD	.451	.203	.15	3.94	<.0001	19

FIG. 2




FIG. 3A




FIG. 3B





FIG. 3C

David E. Comings METHOD OF PROFILING GENES AS RISK FACTORS FOR ATTENTION OF DEFICIT HYPERACTIVITY DISORDER Serial No. 09/825,922 Sheet 11 of 11



 2